S1P1 also plays a significant physiological role as a key regulator of lymphocyte trafficking, and the main pharmacodynamic effect of fingolimod and siponimod lays in their ability to induce a persistent internalization of S1P1 in lymphocytes and subsequent lymphopenia [8]. The gene discussed is S1PR1; the disease is lymphopenia.